6-mercaptopurine reduces macrophage activation and gut epithelium proliferation through inhibition of GTPase Rac1

Inflammatory Bowel Diseases

Volumn 20, Issue 9, 2014, Pages 1487-1495

  Marinković, Goran ^a   Hamers, Anouk A J ^a   De Vries, Carlie J M ^a   De Waard, Vivian ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

6 mercaptopurine; Gut epithelium; IBD; Macrophages; Rac1

Indexed keywords

6 THIOGUANOSINE 5' TRIPHOSPHATE; ANTIINFLAMMATORY AGENT; AZATHIOPRINE DERIVATIVE; CYCLIN D1; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MERCAPTOPURINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN INHIBITOR; RAC1 PROTEIN; RANTES; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; RAC1 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CACO 2 CELL LINE; CELL PROLIFERATION; DNA BINDING; GENE EXPRESSION; GENETIC TRANSFECTION; IMMUNE RESPONSE; INTESTINE EPITHELIUM CELL; MACROPHAGE ACTIVATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; GASTROINTESTINAL TRACT; GENETICS; HUMAN; MACROPHAGE; METABOLISM; MOUSE; PHOSPHORYLATION;

6-MERCAPTOPURINE; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; EPITHELIAL CELLS; GASTROINTESTINAL TRACT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-8; MACROPHAGE ACTIVATION; MACROPHAGES; MAP KINASE KINASE 4; MICE; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHORYLATION; RAC1 GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925852412     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000122     Document Type: Article

References (60)

1. Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7:322-337.
2. Escher JC, Taminiau JA, Nieuwenhuis EE, et al. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis. 2003;9:34-58.
3. Louis E, Belaiche J. Optimizing treatment with thioguanine derivatives in inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 2003;17: 37-46.
4. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993;34:1081-1085.
5. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641-649.
6. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995;37:674-678.
7. Derijks LJ, Gilissen LP, Hooymans PM, et al. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24: 715-729.
8. Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis. 2009;15:375-382.
9. Reinisch W, Panes J, Lemann M, et al. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol. 2008;103:2284-2292.
10. Cuffari C, Theoret Y, Latour S, et al. 6-mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut. 1996;39: 401-406.
11. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther. 2006;23:1097-1104.
12. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.
13. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287:G7-G17.
14. Vermeulen L, De Sousa E Melo F, van der Heijden M, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010;12:468-476.
15. van Schaik FD, van Oijen MG, Smeets HM, et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut. 2012;61:235-240.
16. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329-339.
17. Mudter J, Neurath MF. Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut. 2007;56:293-303.
18. Quemeneur L, Gerland LM, Flacher M, et al. Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J Immunol. 2003;170:4986-4995.
19. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133-1145.
20. Poppe D, Tiede I, Fritz G, et al. Azathioprine suppresses ezrin-radixinmoesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol. 2006;176: 640-651.
21. Marinkovic G, Hibender S, Hoogenboezem M, et al. Immunosuppressive drug azathioprine reduces aneurysm progression through inhibition of Rac1 and c-Jun-terminal-N-kinase in endothelial cells. Arterioscler Thromb Vasc Biol. 2013;33:2380-2388.
22. Marinkovic G, Kroon J, Hoogenboezem M, et al. Inhibition of GTPase Rac1 in endothelium by 6-mercaptopurine results in immunosuppression in nonimmune cells: new target for an old drug. J Immunol. 2014;192: 4370-4378.
23. Clayburgh DR, Shen L, Turner JR. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest. 2004;84:282-291.
24. Soderholm JD, Olaison G, Lindberg E, et al. Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited defect in mucosal defence? Gut. 1999;44:96-100.
25. Henderson P, van Limbergen JE, Schwarze J, et al. Function of the intestinal epithelium and its dysregulation in inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:382-395.
26. Arai F, Takahashi T, Furukawa K, et al. Mucosal expression of interleukin-6 and interleukin-8 messenger RNA in ulcerative colitis and in Crohn's disease. Dig Dis Sci. 1998;43:2071-2079.
27. Nishitani Y, Zhang L, Yoshida M, et al. Intestinal anti-inflammatory activity of lentinan: influence on IL-8 and TNFR1 expression in intestinal epithelial cells. PLoS One. 2013;8:e62441.
28. Zareie M, Singh PK, Irvine EJ, et al. Monocyte/macrophage activation by normal bacteria and bacterial products: implications for altered epithelial function in Crohn's disease. Am J Pathol. 2001;158:1101-1109.
29. Bain CC, Scott CL, Uronen-Hansson H, et al. Resident and proinflammatory macrophages in the colon represent alternative contextdependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol. 2013;6:498-510.
30. Rivollier A, He J, Kole A, et al. Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon. J Exp Med. 2012;209:139-155.
31. Zigmond E, Varol C, Farache J, et al. Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigenpresenting cells. Immunity. 2012;37:1076-1090.
32. Bouma G, Baggen JM, van Bodegraven AA, et al. Thiopurine treatment in patients with Crohn's disease leads to a selective reduction of an effector cytotoxic gene expression signature revealed by whole-genome expression profiling. Mol Immunol. 2013;54:472-481.
33. Pols TW, Bonta PI, Pires NM, et al. 6-mercaptopurine inhibits atherosclerosis in apolipoprotein e∗3-leiden transgenic mice through atheroprotective actions on monocytes and macrophages. Arterioscler Thromb Vasc Biol. 2010;30:1591-1597.
34. Muise AM, Walters T, Xu W, et al. Single nucleotide polymorphisms that increase expression of the guanosine triphosphatase RAC1 are associated with ulcerative colitis. Gastroenterology. 2011;141:633-641.
35. Natoli M, Leoni BD, D'Agnano I, et al. Good caco-2 cell culture practices. Toxicol In Vitro. 2012;26:1243-1246.
36. Dhillon SS, Mastropaolo LA, Murchie R, et al. Higher activity of the inducible nitric oxide synthase contributes to very early onset inflammatory bowel disease. Clin Transl Gastroenterol. 2014;5:e46.
37. Deng L, Zhou JF, Sellers RS, et al. A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am J Pathol. 2010;176:952-967.
38. Li Y, de Haar C, Chen M, et al. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut. 2010;59:227-235.
39. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798-809.
40. Faruqi TR, Gomez D, Bustelo XR, et al. Rac1 mediates STAT3 activation by autocrine IL-6. Proc Natl Acad Sci U S A. 2001;98:9014-9019.
41. Hu X, Yu J, Zhou X, et al. A small GTPase-like protein fragment of mycoplasma promotes tumor cell migration and proliferation in vitro via interaction with Rac1 and Stat3. Mol Med Rep. 2014;9: 173-179.
42. Mattagajasingh SN, Yang XP, Irani K, et al. Activation of Stat3 in endothelial cells following hypoxia-reoxygenation is mediated by Rac1 and protein kinase C. Biochim Biophys Acta. 2012;1823:997-1006.
43. Simon AR, Vikis HG, Stewart S, et al. Regulation of STAT3 by direct binding to the Rac1 GTPase. Science. 2000;290:144-147.
44. Yang XG, Bao YL, Huang YX, et al. 6-[(1-naphthylmethyl)sulfanyl]-9Hpurine induces G2/M phase arrest and apoptosis in human hepatocellular carcinoma HepG2 cells. Eur J Pharmacol. 2012;695:27-33.
45. Jarnicki A, Putoczki T, Ernst M. Stat3: linking inflammation to epithelial cancer: more than a "gut" feeling? Cell Div. 2010;5:14.
46. Wang Z, Jin H, Xu R, et al. Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression. Exp Mol Med. 2009;41:717-727.
47. de Waard V, Arkenbout EK, Vos M, et al. TR3 nuclear orphan receptor prevents cyclic stretch-induced proliferation of venous smooth muscle cells. Am J Pathol. 2006;168:2027-2035.
48. Ferguson LR, Han DY, Fraser AG, et al. Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population. Mutat Res. 2010;690:108-115.
49. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
50. Li Y, de Haar C, Peppelenbosch MP, et al. New insights into the role of STAT3 in IBD. Inflamm Bowel Dis. 2012;18:1177-1183.
51. Durant L, Watford WT, Ramos HL, et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity. 2010;32:605-615.
52. Liu X, Lee YS, Yu CR, et al. Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases. J Immunol. 2008;180: 6070-6076.
53. Abreu-Martin MT, Palladino AA, Faris M, et al. Fas activates the JNK pathway in human colonic epithelial cells: lack of a direct role in apoptosis. Am J Physiol. 1999;276:G599-G605.
54. Xu Z, Maroney AC, Dobrzanski P, et al. The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis. Mol Cell Biol. 2001; 21:4713-4724.
55. Frausto-Del-Rio D, Soto-Cruz I, Garay-Canales C, et al. Interferon gamma induces actin polymerization, Rac1 activation and down regulates phagocytosis in human monocytic cells. Cytokine. 2012;57:158-168.
56. Gulbins E, Coggeshall KM, Brenner B, et al. Fas-induced apoptosis is mediated by activation of a Ras and Rac protein-regulated signaling pathway. J Biol Chem. 1996;271:26389-26394.
57. Mitsuyama K, Suzuki A, Tomiyasu N, et al. Pro-inflammatory signaling by Jun-N-terminal kinase in inflammatory bowel disease. Int J Mol Med. 2006;17:449-455.
58. Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology. 2004;113:427-437.
59. Bid HK, Roberts RD, Manchanda PK, et al. RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis. Mol Cancer Ther. 2013;12:1925-1934.
60. Deng X, Szabo S, Khomenko T, et al. Novel pharmacologic approaches to the prevention and treatment of ulcerative colitis. Curr Pharm Des. 2013; 19:17-28.